ArticleInternational journal of clinical and experimental medicine2015
The association between three IL-6 polymorphisms and HBV-related liver diseases: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis.Medicine · 2019Pooled it
- IL-6 (-174 G/C) and IL-10 (-1082 G/A) polymorphisms and serum levels in Sudanese patients with end-stage renal disease and overt hepatitis B infection: a pilot comparative study.BMC immunology · 2026Article
- Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients.BMC pediatrics · 2024Article
- Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population.Cytokine · 2022Article
- Host Factors in the Natural History of Chronic Hepatitis B: Role of Genetic Determinants.International journal of hepatology · 2022Article
- Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis.Clinical and experimental hepatology · 2020Article
- MicroRNA-146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin-6.Experimental and therapeutic medicine · 2019Article
- [Correlation between interleukin-6 single nucleotide polymorphism and the occurrence and prognosis of hepatitis B virus-associated acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- The regulatory role of IL-6R in hepatitis B-associated fibrosis and cirrhosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
- Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA quantity of case-control studies have been performed to address the association between the three interleukin-6 (IL-6) polymorphisms (-572G/C, -597G/A and -174G/C) and the risk of HBV related liver diseases. However, previous research results are inconsistent. We conducted this meta-analysis to clarify the correlation between these IL-6 polymorphisms and HBV related liver diseases.
methodsWe searched in PubMed, EMBASE, Cochrane Library as well as Chinese databases including China National Knowledge Infrastructure (CNKI) and WanFang database for all the relevant studies up to April 15, 2015. The data were extracted by two independent authors. Odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated.
resultsA total of 10 studies consisting of 3879 cases and 2812 controls were included in this metaanalysis. For IL-6 polymorphism -572G/C, an association with increased chronic hepatitis B (CHB) risk was observed under in allelic, homozygous, heterozygous, dominant and recessive model. However, IL-6 polymorphisms (-572G/C) were not related to Inactive Carrier (IC), Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC) risk in this study. We also found that IL-6 polymorphisms (-597G/A) were related to CHB in allelic, heterozygous, recessive model. For IL-6 polymorphism -174G/C, we did not find any association with CHB risk.
conclusionThe present meta-analysis indicated that IL-6 polymorphisms -572G/C and -597G/A significantly associate with CHB risk, but might not be significantly related to the progressive HBV such as LC and HCC. IL-6 polymorphisms -174G/C might not significantly associate with HBV related liver diseases.
Indexed as
Identifiers
26770294PMC4694194W2336305159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.